The aim of this report is to provide general information about the use of PET and PET-CT in clinical routine, mainly in oncology and to explain with some selected examples what one can see and what one cannot see in PET and PET-CT.




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. M. Pieterman et al. Preoperative staging of non-small-cell lung cancer with positron- emission tomography. N Engl J Med. 2000 Jul 27; 343(4):254-61.CrossRefGoogle Scholar
  2. 2.
    T. Stuckensen et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg. 2000 Dec; 28 (6):319-24.Google Scholar
  3. 3.
    M. G. Mikhaeel et al. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging. 2006 Jul; 33 Suppl 1:22-6.CrossRefGoogle Scholar
  4. 4.
    P. L. Zinzani et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006 Aug; 17(8):1296-300. Epub 2006 Jun 9.CrossRefGoogle Scholar
  5. 5.
    O. Vrieze et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol. 2004 Dec; 73(3):269-75.CrossRefGoogle Scholar
  6. 6.
    P. Seam et al. The role of FDG-PET scans in patients with lymphoma Blood. 2007 Nov 15; 110(10):3507-16. Epub 2007 Aug 20.Google Scholar

Copyright information

© Springer Science+Business Media B.V 2008

Authors and Affiliations

  • Susanne Albrecht
    • 1
  1. 1.Hôpitaux universitaires de GenèveGenève 14Switzerland

Personalised recommendations